Novo Nordisk Will Use Anthropic’s Claude for Drug Research

Live updates

1. 58m ago

   Novo Nordisk Partners With Anthropic to Use Claude in Drug Discovery

   Danish pharmaceutical company Novo Nordisk has formed a partnership with artificial intelligence lab Anthropic to utilize the Claude model and Claude Science tools for accelerating drug discovery and development. The collaboration aims to boost research and development productivity, shorten research timelines, and tackle complex challenges identified by Novo scientists and computational teams. Researchers intend to use the technology to analyze complex data sets, investigate human biology, and understand medication mechanisms. Additionally, Novo Nordisk stock surged 4 percent following the announcement of the artificial intelligence partnership alongside a European drug approval recommendation for Frehemgo.

   Why it matters

   The maker of Wegovy and Ozempic is expanding its technological strategy by bringing artificial intelligence deeper into its laboratory workflows. Pharmaceutical companies increasingly turn to advanced large language models to compress the notoriously lengthy and expensive timelines required to bring new medicines to market. This alliance connects a major global pharmaceutical firm with a prominent artificial intelligence developer aiming to validate systems for biological research.

   What is confirmed

   • Novo Nordisk has partnered with Anthropic to use Claude models and Claude Science tools for drug discovery and development.
   • The collaboration will focus on key drug discovery challenges identified by Novo scientists and computational teams.
   • Researchers will use Claude to analyze complex data, investigate human biology, and understand how drugs work.
   • Novo Nordisk stock surged 4 percent following the announcement of the Anthropic partnership.

   Still unconfirmed

   • Anthropic's Life Sciences Verification Program gives qualifying organizations gated access to its Mythos 5.1 model for drug discovery.

   What to watch next

   • Specific deployment milestones or workflow integration updates from Novo Nordisk and Anthropic
   • Further financial or operational impacts on Novo Nordisk research and development productivity
   Sources used for this update (12)

   1. WSJ — Novo Nordisk Will Use Anthropic’s Claude for Drug Research
   2. Reuters — Novo partners with Anthropic to speed up drug development with Claude
   3. politico.eu — Ozempic-maker turns to Anthropic to turbocharge medical research
   4. Barchart.com — NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery
   5. Bloomberg.com — Novo Will Work With Anthropic AI to Speed Drug Development
   6. blockonomi.com — Novo Nordisk (NVO) Stock Surges 4% on Anthropic AI Collaboration and European Drug Approval
   7. www.indianpharmapost.com — Novo Nordisk and Anthropic join forces to accelerate AI-driven drug discovery
   8. finance.yahoo.com — Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
   9. www.businessreport.com — Novo Nordisk deepens its AI push with Anthropic partnership
   10. healthcare-digital.com — Novo & Anthropic: Partnering on Claude AI Drug Discovery
   11. cryptobriefing.com — Anthropic launches beta Life Sciences Verification Program for AI models
   12. www.digitalhealthnews.com — Novo Nordisk Partners with Anthropic to Advance AI-Driven Drug Discovery
   confidence 95%